Pfizer has awarded $80,000 to Rutgers Robert Wood Johnson Medical School (RWJMS) to fund an Amyloidosis Fellowship at Robert Wood Johnson University Hospital (RWJUH), an RWJBarnabas Health facility. 

Dec. 11, 2024 — Older adults whose blood pressure fluctuates over time may be more likely to have problems with thinking and memory skills, according to a study published in the Dec. 11, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology.

Dec. 11, 2024 — Genetesis, Inc. has launched the CardioFlux Membership program. CardioFlux Membership is designed to be the easiest, fastest, and safest way to repeatedly measure and monitor heart health over the course of a lifetime. Participating Members schedule regular Visits to CardioFlux Imaging Institutes (CIIs) where they receive a heart scan to track changes in their myocardial fitness over time, as measured by a CardioFlux Score.

Dec. 12, 2024 — Physicians have a new treatment option for many of the sickest pediatric patients with heart failure and cardiogenic shock. Johnson & Johnson MedTech has announced that the U.S.

Dec. 13, 2024 – Sensome has announced positive results from two studies of its Clotild Smart Guidewire System demonstrating its ability to successfully identify “fresh” clot – thrombus rich in red blood cells (RBCs) – in peripheral artery disease (PAD) and differentiate it from other tissue encountered during PAD procedures. Results from the SEPARATE and E-SEPARATE studies were presented during a trial session at the Paris Vascular Insights Course in December.

Bally Ribbon Mills (BRM) offers a broad product line of medical textiles and fabrics ideal for use in cardiovascular, orthopedic and dental prosthetic applications.

Tubular prosthesis of medical textiles can become one with the repaired vessel over time and can provide less invasive options than operations like open heart surgery. BRM’s woven seamless tubular materials for stent and knitted grafts offer solutions for aortic repair and endoluminal devices. Other BRM cardiovascular textiles facilitate Trans Aortic Valve Replacement and Aseptal Defect repair.

Dec. 4, 2024  – Cleerly has successfully closed its latest Series C extension funding round, raising a total of $106 million.

Nov. 18, 2024 — In November, Esperion presented  an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented at the 2024 American Heart Association Scientific Sessions, in Chicago, IL. Additionally, two exploratory analyses from the CLEAR Outcomes trial and a real-world analysis of bempedoic acid usage were presented at the conference.

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.

The FDA approval is based on positive results seen in the ATTRibute-CM Phase 3 study, where Attruby significantly reduced death and cardiovascular-related hospitalization, and improved quality of life.

Nov. 21, 2024 — Royal Philips plans to unveil its next-generation 1.5T BlueSeal MR wide-bore scanner at RSNA 2024 in Chicago, Dec. 1-4. The latest generation scanner features a 70 cm wide-bore design and integrates AI-enabled MR Smart Workflow solutions, designed to enhance access and diagnostic confidence to improve outcomes for more patients. The MR Smart Workflow solutions increase daily patient throughput without compromising diagnostic quality to address the needs of high-demand healthcare environments.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now